« Return to News | Drug Sponsors

AB-Biotics, GSK sign agreement to promote Neurofarmagen test in Brazil

Friday, March 22, 2013 04:01 PM

GlaxoSmithKline (GSK) and the Spanish biotech company AB-Biotics, have reached an agreement by which GSK will handle the exclusive promotion of Neurofarmagen, the line of pharmacogenetic tests developed by AB-Biotics.

"The agreement with GlaxoSmithKline will be a major boost for the AB-Biotics turnover in the coming years,” said Miquel Angel Bonachera and Sergi Audivert, co-founders and CEOs of AB-Biotics.

In Brazil, GSK will promote Neurofarmagen, a genetic test developed by AB-Biotics which identifies the safest and most appropriate medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing their DNA, extracted from a sample of saliva. The product will be launched this year in Brazil, where according to estimates by AB-Biotics, there are one million potential patients eligible for Neurofarmagen.

The test is currently marketed in Spain by Almirall following the agreement signed last October.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.